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ABSTRACT
Objectives: The objective of our follow-up study is to
evaluate liver function tests (LFTs) and lipid profiles in
patients with Gilbert’s syndrome treated with
isotretinoin because of severe acne.
Setting: Dermatology outpatient clinics of three
regional hospitals of Jaén (Spain).
Participants: Over 4 years, we included all patients
diagnosed with severe acne. Only 37 patients were
identified, of which 11 had Gilbert’s syndrome.
Interventions: All patients were treated with
isotretinoin and followed-up in our outpatient clinics
after 10 and 20 weeks. Patients were subjected to an
interview questionnaire which included data on age,
gender, complete blood count, coagulation profile,
fasting blood glucose, LFTs and lipid profiles. Data and
results of patients with severe acne and Gilbert’s
syndrome were compared with those of 26 patients
with only severe acne (control group).
Primary outcome: Blood analyses were repeated in
the follow-up visits.
Results: In patients with Gilbert’s syndrome, bilirubin
levels showed substantial decrease over the 20-week
follow-up, with more decrease after 10 weeks. None of
the control group patients had significant increase in
total bilirubin levels after 10 and 20 weeks of follow-
up. Liver enzymes were maintained within normal
levels in both groups. Both study groups did not show
significant pathological increase in lipid profile levels.
LDL levels were increased in the two study groups, but
this increase was less substantial in patients with
Gilbert’s syndrome.
Conclusions: Our preliminary results suggest that
oral isotretinoin could be an effective, safe treatment
for patients with Gilbert’s syndrome, and may lower
bilirubin levels in the first 10 weeks of treatment.
Limitations of the study include the small numbers of
participants and the fact that it is restricted to one
region of Spain.
INTRODUCTION
The use of isotretinoin for the treatment of
severe acne has been widely known over the
past 30 years. Many adverse reactions to
iostretinoin have been reported. Several
studies have shown that hepatotoxicity could
occur in about 10% and hyperlipidaemia in
20–45% of the patients.1–3
Gilbert’s syndrome is a benign and inherited
state characterised by intermittent unconju-
gated hyperbilirubinaemia with accompanying
jaundice in the absence of haemolysis or
underlying liver disease.4 Previous studies have
shown that Gilbert’s syndrome affects 5–7% of
the population, mainly postpubertal male
patients.4 5
In patients with hepatic dysfunction, like
Gilbert’s syndrome, we would expect an
increased sensitivity to isotretinoin that is
metabolised by hepatic oxidation and biliary
excretion.6 7
The objective of our follow-up study is to
evaluate liver function tests (LFTs) and lipid
profiles in patients with Gilbert’s syndrome
treated with isotretinoin because of severe
acne.
METHODOLOGY
All patients with severe acne who attended
the dermatology outpatient clinics of the
three regional hospitals of Andújar, Alcala la
Real and Alcaudete ( Jaén, Spain) over
4 years were eligible to be included in our
study. Owing to the location of these three
regional hospitals in the centre of Andalusia,
they serve over one million persons. The
study was approved by the Ethical Committee
of Alto Guadalquivir Hospital (Andújar,
Spain).
Strengths and limitations of this study
▪ All patients with severe acne who attended the
dermatology outpatient clinics over 4 years were
eligible to be included in our study.
▪ Limitations of the study include the small
numbers of participants and the fact that it is
restricted to one region of Spain.
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Only patients with severe acne and treated with isotre-
tinoin from 1 September 2008 to 31 August 2012 were
included consecutively in the study.
Severe acne was diagnosed according to the European
evidence-based (S3) guidelines for the treatment of
acne.8
Inclusion criteria were age between 14 and 20 years
old, severe acne, treatment with oral isotretinoin
(0.5–0.8 mg/kg) and normal LFTs and lipid profiles.
Meanwhile, exclusion criteria were contradictions for
isotretinoin, concomitant use before or during the study
of other treatment inducer of cytochrome P450, alcohol
consumption, significant change in weight (>10%) and
suspension of the treatment.
We identified 37 patients with severe acne during the
study period, of which 11 had Gilbert’s syndrome.
All patients were informed about the aim of the study
and signed an informed consent.
Patients were subjected to an interview questionnaire
which included data on age, gender, complete blood
count, coagulation profile, fasting blood glucose, liver
function tests and lipid profiles. All questionnaire data
were collected by the first author (PFCS) in the derma-
tology outpatient clinics of the three regional hospitals
of Andújar, Alcala la Real and Alcaudete and the blood
tests were performed at the laboratories of the same
hospitals.
Basal levels of bilirubin in patients with Gilbert’s syn-
drome were measured on three consecutive mornings.
Of the three measures, the mean basal level was calcu-
lated. Fasting levels of bilirubin in patients with Gilbert’s
syndrome were >1.1 mg/dL.
All patients were followed up in our outpatient clinics
after 10 and 20 weeks. Blood analyses were repeated in
the follow-up visits. All participants were followed-up
over 20 weeks with no lost follow-up.
Data and results of patients with severe acne and
Gilbert’s syndrome were compared with those of the 26
patients with only severe acne (control group).
No adverse effects of isotretinoin treatment were
noted and in all patients the acne was in complete remis-
sion at the last follow-up visit.
Statistical methods
First, the following descriptive analysis was performed:
frequency, per cent, mean, SD. Comparisons between
patients with Gilbert’s syndrome and control patients
were performed using Mann-Whitney test for continuous
variables and Pearson’s χ2 test for categorical variables.
Comparisons of LFTs and lipid profile levels over the
follow-up period were performed using Friedman test.
Level of significance was set at p<0.05. All data variables
were encoded and computerised. Data entry and statis-
tical analysis were performed using the Statistical
Package for Social Science (SPSS) V.15.0 (SPSS Inc,
Chicago, Illinois, USA).
RESULTS
Our follow-up study included 37 patients with severe
acne; 11 patients with Gilbert’s syndrome and 26 control
patients. No significant statistical significant differences
were found between the two study groups regarding age
and gender.
In patients with Gilbert’s syndrome, bilirubin levels
showed substantial decrease over the 20-week follow-up,
with more decrease after 10 weeks compared with the
basal level (p value <0.001). Meanwhile, aspartate ami-
notransferase (AST), alanine transaminase (ALT) and
γ-glutamyl transpeptidase (GGT) levels over the 20-week
follow-up did not vary significantly; p values 0.37, 0.77
and 0.46, respectively (table 1).
In control patients, bilirubin and ALT levels did not
vary significantly over the 20-week follow-up; p value 0.23
and 0.28, respectively. Meanwhile, AST and GGT varied
significantly over the 20-week follow-up; p value 0.018
and 0.002, respectively (table 1).
Table 1 Follow-up and comparative study of liver function tests in controls and patients with Gilbert’s syndrome treated with
isotretinoin
Case/variable Gilbert’s syndrome Control p Value*
Basal bilirubin levels 1.78±0.65 0.50±0.22 <0.001
Bilirubin levels after 10 weeks 1.03±0.18 0.52±0.27 <0.001
Bilirubin levels after 20 weeks 1.38±0.54 0.48±0.26 <0.001
Basal AST levels 22.1±5.1 21.6±14.7 0.14
AST levels after 10 weeks 23.8±5.4 21.4±7.8 0.11
AST levels after 20 weeks 21.5±7.1 21.4±7.6 0.95
Basal ALT levels 20±10.4 15.4±9.0 0.12
ALT levels after 10 weeks 21.1±7.9 15.8±6.6 <0.05
ALT levels after 20 weeks 18.2±7.3 15.5±6.4 0.25
Basal GGT levels 18.1±9.9 14±4.7 0.35
GGT levels after 10 weeks 24±1.7 17.1±7.9 0.23
GGT levels after 20 weeks 17.1±4.5 18.4±8.5 0.79
*Mann–Whitney test.
ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, γ-glutamyl transpeptidase.
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In patients with Gilbert’s syndrome, LDL levels
showed substantial increase over the 20-week follow-up,
with more increase after 10 weeks compared with the
basal level (p value <0.001). Meanwhile, cholesterol, tri-
glycerides and high-density lipoprotein (HDL) levels
over the 20- week follow-up did not vary significantly; p
values 0.18, 0.65 and 0.32, respectively (table 2).
In control patients, cholesterol, triglycerides and low-
density lipoprotein (LDL) levels showed substantial
increase over the 20-week follow-up; p value <0.001.
Meanwhile, HDL levels over the 20- week follow-up did
not vary significantly; p value 0.34 (table 2).
DISCUSSION
The main objective of the current follow-up study was to
evaluate the hepatotoxicity of isotretinoin in patients
with Gilbert’s syndrome. In theory, hepatotoxic drugs
such as isotretinoin would increase bilirubin and liver
enzyme levels in patients with hereditary hepatic disor-
ders such as Gilbert’s syndrome.4
Before reaching conclusions based on the present
results, it is necessary to consider a number of potential
objections to the methodology. Limitations such as the
small sample size could affect the validity of the results.
Our study included only 37 patients with severe acne and
treated with oral isotretinoin. It was difficult to identify
more patients according to our strict inclusion and exclu-
sion criteria, and that is why we included all patients
treated over 4 years in three regional hospitals. Other pos-
sible limitations were the placebo effect and the natural
evolution. Placebo effect was avoided by repeated mea-
sures; before treatment, and 10 and 20 weeks after treat-
ment. Natural evolution was controlled by the follow-up
comparative control group without Gilbert’s syndrome.
Although these results pertain solely to a region of the
province of Jaén (Spain) and should not be considered
generalisable, the methodology can be applied in different
dermatology outpatient clinics. Our results call for further
investigation of hepatotoxicity of isotretinoin in patients
with acne and Gilbert’s syndrome; future studies prefer-
ably should be performed on large prospective cohorts, to
increase their internal validity.
By 10 weeks all patients with Gilbert’s syndrome had a
significant decrease in total bilirubin levels and they
maintained this decrease after 20 weeks.
The cause for decline in bilirubin levels in patients
with Gilbert’s syndrome treated with isotretinoin is still
unknown. Only few studies were published about this
unexpected decline in bilirubin levels by a hepatotoxic
drug like isotretinoin.9–11
Several drugs such as phenobarbitals and corticoster-
oids induce microsomal enzymes as uridine diphosphate
glucuronyltransferase (UDP-GT) and stimulate the con-
jugation of bilirubin causing its decline. On the contrary,
isotretinoin inhibits the inducer effect of other drugs
and thus this does not seems to be its mechanism of
action in patients with Gilbert’s syndrome.12 13
Currently, there are two hypotheses to explain this
unexpected effect of isotretinoin in patients with
Gilbert’s syndrome; reversible decrease in the serum
levels of testosterone increasing the activity of UDP-GT
or stimulating hepatocytes to generate transporting pro-
teins that eliminate bilirubin.14 15
None of the control group patients had significant
increase in total bilirubin levels after 10 and 20 weeks of
follow-up. It is of note that liver enzymes (AST, ALT and
GGT) were maintained within normal levels in both
study groups.
Our study also explored the adverse effect of isotretinoin
on lipid profile levels. Both study groups did not show sig-
nificant pathological increase in lipid profile levels (chol-
esterol, triglycerides, HDL and LDL). All lipid profile
levels in patients with Gilbert’s syndrome and control
patients were maintained within the normal recom-
mended levels. Recent follow-up study with 248 patients
treated with isotretinoin because of acne vulgaris showed
that only 1.2% suffered impaired LFTs and 1.61% had
Table 2 Follow-up and comparative study of lipid profile in controls and patients with Gilbert’s syndrome treated with
isotretinoin
Case/variable Gilbert’s syndrome Control p Value*
Basal cholesterol levels 143.6±19.5 155.6±24.7 0.09
Cholesterol levels after 10 weeks 164.4±23.4 176.3±30 0.32
Cholesterol levels after 20 weeks 162.7±12.4 181.6±30.5 0.11
Basal triglycerides levels 71.2±27.2 72.1±43 0.54
Triglycerides levels after 10 weeks 84.3±50.7 93.5±46.4 0.27
Triglycerides levels after 20 weeks 67.2±31 103.8±56.9 <0.05
Basal HDL levels 53.5±15.2 56.7±11.4 0.33
HDL levels after 10 weeks 53.5±14.8 56.7±12.8 0.46
HDL levels after 20 weeks 62.4±17.5 54.8±13.6 0.23
Basal LDL levels 78.1±13.9 82.3±20.5 0.54
LDL levels after 10 weeks 95.3±19 99.4±25.6 0.71
LDL levels after 20 weeks 88.3±14.1 107.3±24.5 <0.05
*Mann–Whitney test.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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high-lipid profile levels after 16 weeks of treatment.16
These findings agree with our results after 10 and
20 weeks of follow-up in patients with Gilbert’s syndrome
and control patients.
LDL levels were increased in the two study groups, but
this increase was less substantial in patients with Gilbert’s
syndrome. Again, these findings are contradictory to
what would be expected from hepatotoxic drug admini-
strated in patients with hepatic dysfunction.
Previous studies showed that patients with Gilbert’s syn-
drome have lower prevalence of atherosclerosis and
ischaemic heart disease.17 18 A systematic review confirmed
that there is a reliable inverse and dose–response relation-
ship between serum bilirubin and the atherosclerotic
process.19 Recent case–control study showed that LDL, a
well-known mediator of initial stages of atherosclerosis, was
lower in patients with Gilbert’s syndrome when compared
with healthy controls.20 This agrees with the results of our
study where basal levels of LDL and after isotretinoin treat-
ment were lower in patients with Gilbert’s syndrome com-
pared with control patients.
In conclusion, our preliminary results suggest that oral
isotretinoin is not only an effective safe treatment
for patients with Gilbert’s syndrome, but also it lowers
bilirubin levels in the first 10 weeks of treatment.
Identification of the mechanism of action of oral isotreti-
noin in patients with Gilbert’s syndrome could help in
elaborating new protective drugs against hepatotoxicity.
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